Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo

Cancer Research

Volumn 60, Issue 18, 2000, Pages 5165-5170

  Butler, L M ^a   Agus, D B ^a   Scher, H I ^a   Higgins, B ^a   Rose, A ^a   Cordon Cardo, C ^a   Thaler, H T ^a   Rifkind, R A ^a   Marks, P A ^a   Richon, V M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; SUBEROYLANILIDE HYDROXAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMAL; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL DIVISION; ENZYME INHIBITORS; GROWTH INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMAN; HYDROXAMIC ACIDS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034665124     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Differentiation: A suitable strategy for cancer chemotherapy?
2. Induced differentiation, the cell cycle, and the treatment of cancer
3. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation
4. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
5. The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells
6. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA)
7. Chemopreventive efficacy of suberanilo-hydroxamic acid (SAHA), a cytodifferentiating agent, against tobacco-specific nitrosamine 4-(methylnitros-amino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice
8. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
9. The nucleosome: A powerful regulator of transcription
10. Histone acetylation and transcriptional regulatory mechanisms
11. Cancer of the prostate
12. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate
13. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
14. Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo
15. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model
16. Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid
17. Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, 1α,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate
18. 1
19. 3 on primary cultures of human prostatic cells
20. 3 in seven human prostatic carcinoma cell lines
21. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion
22. 3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells
23. Xenografts of primary human prostatic carcinoma
24. CWR22: Androgen-dependent xenograft model derived from a primary human prostatic carcinoma
25. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar
26. Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence
27. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation
28. Single-step method of RNA isolation by acid guanidinium thiocyanate- phenol-chloroform extraction
29. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A
30. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma
31. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
32. Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells